CytomX Therapeutics (CTMX) Enterprise Value (2016 - 2025)
CytomX Therapeutics (CTMX) has disclosed Enterprise Value for 12 consecutive years, with -$143.6 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Enterprise Value fell 22.14% year-over-year to -$143.6 million, compared with a TTM value of -$143.6 million through Sep 2025, down 22.14%, and an annual FY2024 reading of -$100.6 million, up 42.34% over the prior year.
- Enterprise Value was -$143.6 million for Q3 2025 at CytomX Therapeutics, up from -$158.1 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$79.9 million in Q1 2025 and bottomed at -$393.8 million in Q1 2021.
- Average Enterprise Value over 5 years is -$195.9 million, with a median of -$193.6 million recorded in 2022.
- The sharpest move saw Enterprise Value plummeted 58.84% in 2021, then skyrocketed 46.84% in 2025.
- Year by year, Enterprise Value stood at -$305.2 million in 2021, then surged by 36.56% to -$193.6 million in 2022, then grew by 9.88% to -$174.5 million in 2023, then surged by 42.34% to -$100.6 million in 2024, then plummeted by 42.74% to -$143.6 million in 2025.
- Business Quant data shows Enterprise Value for CTMX at -$143.6 million in Q3 2025, -$158.1 million in Q2 2025, and -$79.9 million in Q1 2025.